Sign Up
OverviewAPI
Aptose Biosciences closes a $9.7 million public offering of common shares and warrants led by Newbridge Securities Corporation and including a strategic investment by Hanmi Pharmaceutical. The net proceeds will support clinical trials for tuspetinib, manufacturing of tuspetinib clinical supplies, and working capital.

Ask a question